Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study.
Lung cancer
Molecular alterations
Prognostic awareness
Quality of life
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
05
02
2021
accepted:
30
11
2021
pubmed:
9
12
2021
medline:
23
2
2022
entrez:
8
12
2021
Statut:
ppublish
Résumé
The purpose of this study is to investigate changes over time in quality of life (QoL) in incurable lung cancer patients and the impact of determinants like molecular alterations (MA). In a prospective, longitudinal, multicentric study, we assessed QoL, symptom burden, psychological distress, unmet needs, and prognostic understanding of patients diagnosed with incurable lung cancer at the time of the diagnosis (T0) and after 3 (T1), 6 (T2) and 12 months (T3) using validated questionnaires like FACT-L, National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT), PHQ-4, SCNS-SF-34, and SEIQoL. Two hundred seventeen patients were enrolled, 22 (10%) with reported MA. QoL scores improved over time, with a significant trend for DT, PHQ-4, and SCNS-SF-34. Significant determinants for stable or improving scores over time were survival > 6 months, performance status at the time of diagnosis, and presence of MA. Patients with MA showed better QoL scores (FACT-L at T1 104.4 vs 86.3; at T2 107.5 vs 90.0; at T3 100.9 vs 92.8) and lower psychological distress (NCCN DT at T1 3.3 vs 5; at T2 2.7 vs 4.5; at T3 3.7 vs 4.5; PHQ-4 at T1 2.3 vs 4.1; at T2 1.7 vs 3.6; at T3 2.2 vs 3.6), but also a worsening of the scores at 1 year and a higher percentage of inaccurate prognostic understanding (27 vs 17%) compared to patients without MA. Patients with tumors harboring MA are at risk of QoL deterioration during the course of the disease. Physicians should adapt their communication strategies in order to maintain or improve QoL.
Identifiants
pubmed: 34877613
doi: 10.1007/s00520-021-06736-2
pii: 10.1007/s00520-021-06736-2
pmc: PMC8857091
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3131-3140Informations de copyright
© 2021. The Author(s).
Références
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953
pubmed: 30350310
Iyer S, Taylor-Stokes G, Roughley A (2013) Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany. Lung Cancer 81:288–293
pubmed: 23561304
Chabowski M, Polański J, Mazur G, Janczak D, Rosińczuk J. Sociodemographic and clinical determinants of quality of life of patients with non-small cell lung cancer. Adv Exp Med Biol. 2017. p. 1–10.
Graves KD, Arnold SM, Love CL, Kirsh KL, Moore PG, Passik SD (2007) Distress screening in a multidisciplinary lung cancer clinic: prevalence and predictors of clinically significant distress. Lung Cancer 55:215–224
pubmed: 17084483
Sanders SL, Bantum EO, Owen JE, Thornton AA, Stanton AL (2010) Supportive care needs in patients with lung cancer. Psychooncology 19:480–489
pubmed: 19434625
Nipp RD, El-Jawahri A, Fishbein JN, Eusebio J, Stagl JM, Gallagher ER et al (2016) The relationship between coping strategies, quality of life, and mood in patients with incurable cancer. Cancer. 122:2110–2116
pubmed: 27089045
Jordhoy MS, Fayers P, Loge JH, Saltnes T, Ahlner-Elmqvist M, Kaasa S (2001) Quality of life in advanced cancer patients: The impact of sociodemographic and medical characteristics. Br J Cancer 85:1478–1485
pubmed: 11720432
pmcid: 2363932
Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31:233–240
pubmed: 11165402
Zimmermann C, Burman D, Swami N, Krzyzanowska MK, Leighl N, Moore M et al (2011) Determinants of quality of life in patients with advanced cancer. Support Care Cancer Germany 19:621–629
Lundh Hagelin CL, Seiger Å, Fürst CJ (2006) Quality of life in terminal care - with special reference to age, gender and marital status. Support Care Cancer 14:320–328
pubmed: 16189646
Tang ST, Chang WC, Chen JS, Chou WC, Hsieh CH, Chen CH (2016) Associations of prognostic awareness/acceptance with psychological distress, existential suffering, and quality of life in terminally ill cancer patients’ last year of life. Psychooncology 25:455–462
pubmed: 26283000
Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ et al (2011) Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol 29:2319–2326
pubmed: 21555700
Lee MK, Baek SK, Kim SY, Heo DS, Yun YH, Park SR et al (2013) Awareness of incurable cancer status and health-related quality of life among advanced cancer patients: a prospective cohort study. Palliat Med 27:144–154
pubmed: 22143041
Tang ST, Liu TW, Tsai CM, Wang CH, Chang GC, Liu LN (2008) Patient awareness of prognosis, patient-family caregiver congruence on the preferred place of death, and caregiving burden of families contribute to the quality of life for terminally ill cancer patients in Taiwan. Psychooncology 17:1202–1209
pubmed: 18521969
El-Jawahri A, Traeger L, Park ER, Greer JA, Pirl WF, Lennes IT et al (2014) Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer. Cancer 120:278–285
pubmed: 24122784
Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Gallagher ER et al (2014) Perceptions of health status and survival in patients with metastatic lung cancer. J Pain Symptom Manage 48:548–557
pubmed: 24680623
McFarland DC, Jutagir DR, Rosenfeld B, Pirl W, Miller AH, Breitbart W et al (2019) Depression and inflammation among epidermal growth factor receptor (EGFR) mutant nonsmall cell lung cancer patients. Psychooncology 28:1461–1469
pubmed: 31022775
pmcid: 6610756
Harrison PT, Vyse S, Huang PH (2020) Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol 61:167–179
pubmed: 31562956
pmcid: 7083237
Chia PL, Dobrovic A, Dobrovic A, John T (2014) Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014:423–432
Kuon J, Vogt J, Mehnert A, Alt-Epping B, Van Oorschot B, Sistermanns J et al (2019) Symptoms and needs of patients with advanced lung cancer: early prevalence assessment. Oncol Res Treat 42:650–659
pubmed: 31634889
Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P (1995) Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer 12:199–220
pubmed: 7655830
Jacobsen PB, Donovan KA, Trask PC, Fleishman SB, Zabora J, Baker F et al (2005) Screening for psychologic distress in ambulatory cancer patients: a multicenter evaluation of the distress thermometer. Cancer 103:1494–1502
pubmed: 15726544
Löwe B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K et al (2010) A 4-item measure of depression and anxiety: validation and standardization of the patient health questionnaire-4 (PHQ-4) in the general population. J Affect Disord 122:86–95
pubmed: 19616305
Lehmann C, Koch U, Mehnert A (2012) Psychometric properties of the German version of the short-form supportive care needs survey questionnaire (SCNS-SF34-G). Support. Care Cancer. 20:2415–2424
pubmed: 22212457
McGee HM, O’Boyle CA, Hickey A, O’Malley K, Joyce CRB (1991) Assessing the quality of life of the individual: the SEIQoL with a healthy and a gastroenterology unit population. Psychol Med 21:749–759
pubmed: 1946863
Venuta F, Diso D, Onorati I, Anile M, Mantovani S, Rendina EA (2016) Lung cancer in elderly patients. J. Thorac. Dis. 8:S908–S914
pubmed: 27942414
pmcid: 5124601
Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061–2067
pubmed: 10615079
Van Der Weijst L, Lievens Y, Schrauwen W, Surmont V (2019) Health-related quality of life in advanced non-small cell lung cancer: a methodological appraisal based on a systematic literature review. Front Oncol. 9:715
Visser MRM, Smets EMA, Sprangers MAG, De Haes HJCJM (2000) How response shift may affect the measurement of change in fatigue. J Pain Symptom Manage. 20:12–18
pubmed: 10946164
Sammarco A (2009) Quality of life of breast cancer survivors: a comparative study of age cohorts. Cancer Nurs. 32:347–356
pubmed: 19661800
Arndt V, Merx H, Stürmer T, Stegmaier C, Ziegler H, Brenner H (2004) Age-specific detriments to quality of life among breast cancer patients one year after diagnosis. Eur J Cancer 40:673–680
pubmed: 15010067
Akechi T (2012) Psychotherapy for depression among patients with advanced cancer. Jpn. J. Clin. Oncol. 42:1113–1119
pubmed: 23018580
Watson M, Davolls S, Mohammed K, Shepherd S (2015) The influence of life stage on supportive care and information needs in cancer patients: does older age matter? Support Care Cancer 23:2981–2988
pubmed: 25711656
Morrison EJ, Novotny PJ, Sloan JA, Yang P, Patten CA, Ruddy KJ et al (2017) Emotional problems, quality of life, and symptom burden in patients with lung cancer. Clin Lung Cancer 18:497–503
pubmed: 28412094
Eichler M, Hechtner M, Wehler B, Buhl R, Stratmann J, Sebastian M et al (2018) Psychological distress in lung cancer survivors at least 1 year after diagnosis—results of a German multicenter cross-sectional study. Psychooncology 27:2002–2008
pubmed: 29761591
Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18:893–903
pubmed: 10673533
Pirl WF, Traeger L, Greer JA, Jackson V, Lennes IT, Gallagher E, et al. Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer. Palliat. Support. Care. 2013. p. 223–229.
Pirl WF, Traeger L, Greer JA, Bemis H, Gallagher E, Lennes I et al (2011) Tumor Epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer. Oncologist 16:1299–1306
pubmed: 21807767
pmcid: 3228168
Howren MB, Lamkin DM, Suls J (2009) Associations of depression with c-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med 71:171–186
pubmed: 19188531
Wium-Andersen MK, Ørsted DD, Nielsen SF, Nordestgaard BG (2013) Elevated C-reactive protein levels, psychological distress, and depression in 73131 individuals. JAMA Psychiat 70:176–184
Castellanos EH, Horn L. Generations of epidermal growth factor receptor tyrosine kinase inhibitors: perils and progress. Curr. Treat. Options Oncol. 2015.
Tan CS, Cho BC, Soo RA. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer. 2016. p. 59–68.
Marschner N, Zacharias S, Lordick F, Hegewisch-Becker S, Martens U, Welt A et al (2020) Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer. JAMA Netw open. 3:e200643
pubmed: 32154886
pmcid: 7064873
Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L et al (2017) Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget 8:21903–21917
pubmed: 28423535
pmcid: 5400633
Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA et al (2020) Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer 144:10–19
pubmed: 32344248